Tucker Kelly

Canaccord Adams, Inc. is an independent financial services firm and broker/dealer headquartered in Boston with additional offices in New York City, San Francisco, Evanston, Illinois and Houston, Texas. The firm provides research to help clients make informed investment decisions. Their analysts seek to identify opportunities and expose risk with a focus on emerging and small- to mid-cap growth companies. Canaccord Adams focuses on seven sectors, clarifying current events and anticipating market trends in high-quality daily, weekly and monthly research products. The seven sectors they focus on are: metals and mining, energy, technology, life sciences, real estate and gaming, consumer and industrial growth. Canaccord Adams is a subsidiary of Vancouver-based Canaccord Financial, Inc. They are a member of the NASD and the SIPC.

Foley Hoag LLP provides legal services. It offers international litigation and arbitration services, and counsel in the evolving field of corporate social responsibility. The firm offers practices in industries such as life sciences, health care, technology, energy and renewable, investment management, and professional services. The company was founded in 1943 and is headquartered in Boston, MA.

deCODE genetics engages in a biopharmaceuticals company. It provides research services with focus on human genes. The company was founded by K?ri Stef?nsson in August 1996 and is headquartered in Reykjavik, Iceland.

AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA.

Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.